1 What is claimed is:

4

5

6 1

1

1

1

1

1

1

1

6 1

- 2 1. An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3,
 - SEQ ID NO:4, or SEQ ID NO:6, or a full complement thereof; and
 - b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.
- 2 2. The nucleic acid molecule of claim 1, further comprising vector nucleic acid sequences.
- 2 3. The nucleic acid molecule of claim 1, further comprising nucleic acid sequences encoding a heterologous polypeptide.
- 2 4. A host cell which contains the nucleic acid molecule of claim 1.
- 5. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ
 ID NO:5.
- 2 6. The polypeptide of claim 5 further comprising heterologous amino acid sequences.
- 2 7. An antibody or antigen-binding fragment thereof that selectively binds to a polypeptide of claim 5.
- 8. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, the method comprising culturing the host cell of claim 4 under conditions in which the nucleic acid molecule is expressed.
- 9. A method for detecting the presence of a polypeptide of claim 5 in a sample,
 comprising:
- a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
 - b) determining whether the compound binds to the polypeptide in the sample.
- The method of claim 9, wherein the compound which binds to the polypeptide is an antibody.

1

2

11.

3	instructions for use.			
1				
2	12.	A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample,		
3	comprising the steps of:			
4		a) contacting the sample with a nucleic acid probe or primer which selectively		
5	hybridizes to the nucleic acid molecule; and			
6		b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule		
7	in the sample.			
1				
2	13.	The method of claim 12, wherein the sample comprises mRNA molecules and is		
3	contacted with a nucleic acid probe.			
1				
2	14.	A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of		
3	claim 1 and instructions for use.			
1				
2	15.	A method for identifying a compound which binds to a polypeptide of claim 5		
3	comprising the steps of:			
4		a) contacting a polypeptide, or a cell expressing a polypeptide of claim 5 with a test		
5	compound; and			
6		b) determining whether the polypeptide binds to the test compound.		
1				
2	16.	A method for modulating the activity of a polypeptide of claim 5, comprising		
3	contac	cting a polypeptide or a cell expressing a polypeptide of claim 5 with a compound which		
4	binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.			
1				

3

5 1

2

3

2

17.

inhibit the aberrant activity of the cell.

18. The method of claim 17, wherein the compound is selected from the group consisting of a peptide, a phosphopeptide, a small organic molecule, and an antibody.

A method of inhibiting aberrant activity of a 21627 or 55562-expressing cell,

comprising contacting a 21617 or 55562-expressing cell with a compound that modulates the

activity or expression of a polypeptide of claim 5, in an amount which is effective to reduce or

A kit comprising a compound which selectively binds to a polypeptide of claim 5 and

2	19.	The method of claim 17, wherein the cell is a 21617-expressing cell located in a
3	cancer	rous or pre-cancerous tissue.

4

1

5 20. The method of claim 19, wherein the cancerous or pre-cancerous tissue is found in the colon, lung, liver, or cervix.

7

- 8 21. A method of treating or preventing a disorder characterized by aberrant activity of a
- 9 21617 or 55562-expressing cell, in a subject, comprising:
- administering to the subject an effective amount of a compound that modulates the activity or expression of a protein molecule of claim 5, such that the aberrant activity of the 21617 or 55562-expressing cell is reduced or inhibited.

13

- 14 22. The method of claim 21, wherein the cell is a 21617-expressing cell located in a
- 15 cancerous or pre-cancerous tissue.